FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	VAL				
OMB Number:	3235-0287				
Estimated average burde	en				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GREEN DAVID						2. Issuer Name and Ticker or Trading Symbol HARVARD BIOSCIENCE INC [HBIO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) 84 OCT	(F OBER HIL	First) L ROAD	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/19/2012									Officer (give title below) President Other below)				(specify		
(Street) HOLLISTON MA 01746 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				ı		
(- 9)		•		on-De	rivati	ve S	ecui	rities Ac	auire	d. Di	sposed of	f. or Be	neficia	ally (Owned					
1. Title of Security (Instr. 3)					saction /Day/Yea	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		(A) or		5. Amount of Securities Beneficially Owned Followin		Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reported Transacti (Instr. 3 a	ion(s)			(Instr. 4)	
Common	12/19/2012							48,146	A	\$3.	16	1,665,079		D						
Common Stock				12/19/2012		2			S		48,146	D	\$4.03	38 ⁽¹⁾	1,616,933		D			
Common Stock					12/20/2012			2			73,591	A	\$3.	16	1,690,524		D			
Common Stock					12/20/2012			2			73,591	D	\$4.05	13 ⁽²⁾	1,616,933		D			
Common Stock 12					1/2012	2			M		14,409	A	\$3.	16	1,631,342		D			
Common Stock			12/21/2012		12		S		14,409	D \$4.0		9 ⁽³⁾	1,616,933(4)			D				
			Table II								posed of, convertib				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion or Exercise (Month/Day/Year) Execution if any (Month/Day/Year) (Month/Day/Year)		ed	4. Transa	ansaction ode (Instr.		5. Number of Derivative			rcisable and Date	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		unt 8	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amou or Numb of Share	oer		(Instr. 4)	on(s)			
Stock Option (right to buy)	\$3.16	12/19/2012			М			48,146 ⁽⁵⁾	01/01	1/2004	04/08/2013	Common Stock, par value \$0.01 per share	48.1	46	\$3.16	88,00	0	D		
Stock Option (right to buy)	\$3.16	12/20/2012			М			73,591 ⁽⁵⁾	01/01	1/2004	04/08/2013	Commor Stock, par value \$0.01 per share	73,5	91	\$3.16	14,409		D		
Stock Option	\$3.16	12/21/2012			М			14 409(5)	01/01	1/2004	04/08/2013	Commor Stock,		09	\$3.16	0		D		

Explanation of Responses:

- 1. Reflects the weighted average price of the shares sold in the reported transaction. These shares were sold in multiple transactions at prices ranging from \$4.0100 to \$4.1400, inclusive. The reporting person undertakes to provide to Harvard Bioscience, Inc., any security holder of Harvard Bioscience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 2. Reflects the weighted average price of the shares sold in the reported transaction. These shares were sold in multiple transactions at prices ranging from \$4.0000 to \$4.1400, inclusive. The reporting person undertakes to provide to Harvard Bioscience, Inc., any security holder of Harvard Bioscience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. Reflects the weighted average price of the shares sold in the reported transaction. These shares were sold in multiple transactions at prices ranging from \$3.9300 to \$4.0800, inclusive. The reporting person undertakes to provide to Harvard Bioscience, Inc., any security holder of Harvard Bioscience, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 4. Includes (a) a deferred stock award of 66,800 restricted stock units which vest in equal installments on Jan 1, 2014; (b) a deferred stock award of 40,312 restricted stock units which vest in equal installments on Jan 1, 2013, Jan 1, 2014 and Jan 1, 2015; (c) a deferred stock award of 88,737 restricted stock units which vest in equal installments on Jan 1, 2013, Jan 1, 2014, Jan 1, 2015 and Jan 1, 2016; and (d) 1,421,084 shares of common stock held by Mr. Green.
- 5. Represents exercise of stock options granted pursuant to the Issuer's 2000 Stock Option and Incentive Plan.

Remarks:

(right to

buy)

This form has been signed under power of attorney.

\$0.01 per

share

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.